Free press releases distribution network?

More news: Health/Surgery
Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Affordable and Innovative Solutions to Drive European Autoimmune Diseases Therapeutics Market - Frost & Sullivan, finds that the European Auto-immune Diseases Therapeutics Market earned revenues of $5.40 billion in 2006 and estimates this to reach $18.74 billion in 2013
Affordable and Innovative Solutions to Drive European Autoimmune Diseases Therapeutics Market

 

PRZOOM - /newswire/ - London, United Kingdom, 2007/01/31 - Frost & Sullivan, finds that the European Auto-immune Diseases Therapeutics Market earned revenues of $5.40 billion in 2006 and estimates this to reach $18.74 billion in 2013.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

An expanding patient base, ongoing awareness campaigns and the acceptance of biologics by physicians are spurring growth in the European autoimmune diseases therapeutics market. With over 70 autoimmune diseases including rheumatoid arthritis and multiple sclerosis (MS), there exists tremendous scope in translating current knowledge to producing innovative, efficient and economical therapeutics.

Frost & Sullivan (pharma.frost.com) finds that the European Autoimmune Diseases Therapeutics Market earned revenues of $5.40 billion in 2006 and estimates this to reach $18.74 billion in 2013.

"The growing patient population and the need for better treatment options are the major driving forces in market growth," says Frost & Sullivan Industry Analyst Sylvia Miriyam Findlay.

The estimated prevalence rate of MS in Europe is 83 of 100,000 with the average annual number of new cases pegged at 4.3 per 100,000. Moreover, Europe has 103 million arthritis sufferers, including nearly 2 million with rheumatoid arthritis; resulting in a $65 billion burden. This situation has created a compelling need for innovative, effective and affordable therapeutics.

"The rising uptake of biologics by physicians will have a significant impact on product sales," notes Ms. Findlay. "Aggressive campaigns undertaken by the pharmaceutical companies to promote newer biologics are sparking interest among physicians and will propel revenue generation."

However, the considerable gap between early diagnosis and the actual initiation of therapy remains a critical restraining factor to market growth.

"The complex nature of autoimmune diseases hinders the development of suitable therapeutics," observes Ms. Findlay. "The scenario is worsened by low awareness among patients and physicians as well as by improper communication about methods of effective disease management."

A range of continuous medical education programmes will help disseminate information on autoimmune diseases and their clinical and financial implications. Such initiatives will expand diagnosis and, by extension, the patient population being treated. This will be the key to accelerate market penetration.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis of the European Autoimmune Disease Therapeutics Market (H045-52), send an e-mail to Radhika Menon Theodore - Corporate Communications at rmtherodore[.]frost.com with your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information through email upon receipt of the above information.

European Autoimmune Disease Therapeutics Market is a part of the Pharmaceuticals and Biotechnology Subscription, which also includes research in the following markets: European Respiratory Diseases Market, Pricing & Reimbursement Issues for Generics and Biosimilars Markets in Europe and European Diabetes Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.

Keywords: biologics, physicians, European autoimmune diseases therapeutics market, Europe, autoimmune diseases, autoimmune disease therapeutics, market, rheumatoid arthritis, multiple sclerosis, MS, arthritis sufferers, pharmaceutical companies, disease management, medical education programmes

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


Affordable and Innovative Solutions to Drive European Autoimmune Diseases Therapeutics Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Radhika Menon Theodore 
+91-44-42044541 rmtheodore[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Health/Surgery Most Recent Related Press Releases:

USACS Announces New Integrated Acute Care Partnership with Sharon Regional Health System
Frost & Sullivan Highlights STANLEY Healthcare's Design Innovation and Leadership in Addressing the Changing Needs of the Senior Living Industry
USACS Additional Integrated Acute Care Partnership with MetroSouth Medical Center
Big Data Analytics to Disrupt U.S. Next-generation Sequencing Informatics Market with Double-digit Growth
Bionic Prosthetics Manufacturers Drive R&D Initiatives across Emerging Markets to Impel its Adoption
Frost & Sullivan Acclaims CGI’s Advanced Genomic & Biomarker Technologies That Drive Industry Innovation in Support of Precision Cancer Treatment
Frost & Sullivan Honors Linguamatics for Developing a Best-in-Class NLP-based Data Mining Platform for the Healthcare Industry
Top Innovative Health and Wellness Technologies to Accelerate Global Adoption of Precision Medicine Finds Frost & Sullivan
Rheumatoid Arthritis Diagnosis Tests Market Size to Expand At 6.2% CAGR through 2022 Says PMR
Persistence Market Research Publishes Health Information Exchange Market Opportunities and Forecasts 2017-2025

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  JobsWare.com

Visit  NAKIVO, Inc.

Visit  RightITnow Ltd







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today